Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
作者信息
Mégarbane Bruno, Scherrmann Jean-Michel
机构信息
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.
Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France.
出版信息
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
2
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
3
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
4
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
5
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
6
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):187-188. doi: 10.1007/s10928-020-09689-x. Epub 2020 May 13.
7
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
8
Acute meningoencephalitis in a patient with COVID-19.
Rev Neurol (Paris). 2020 Jun;176(6):519-521. doi: 10.1016/j.neurol.2020.04.014. Epub 2020 May 11.
9
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
J Am Heart Assoc. 2020 Jun 16;9(12):e017144. doi: 10.1161/JAHA.120.017144. Epub 2020 May 28.
10
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
引用本文的文献
1
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
2
Antihistamines as an early treatment for Covid-19.
Heliyon. 2023 May;9(5):e15772. doi: 10.1016/j.heliyon.2023.e15772. Epub 2023 Apr 25.
3
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11.
4
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.
Inflammopharmacology. 2021 Apr;29(2):343-366. doi: 10.1007/s10787-021-00796-w. Epub 2021 Mar 15.
5
Therapeutic Strategies in the Management of COVID-19.
Front Mol Biosci. 2021 Feb 4;7:636738. doi: 10.3389/fmolb.2020.636738. eCollection 2020.
6
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.
Pulm Pharmacol Ther. 2021 Apr;67:101989. doi: 10.1016/j.pupt.2021.101989. Epub 2021 Jan 16.
7
Utilitarian Principlism as a Framework for Crisis Healthcare Ethics.
HEC Forum. 2021 Jun;33(1-2):45-60. doi: 10.1007/s10730-020-09431-7. Epub 2021 Jan 15.
8
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
Rheumatol Int. 2021 Feb;41(2):257-273. doi: 10.1007/s00296-020-04759-2. Epub 2021 Jan 1.
9
SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management.
Microorganisms. 2020 Sep 24;8(10):1468. doi: 10.3390/microorganisms8101468.
10
Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?
Biochimie. 2020 Dec;179:266-274. doi: 10.1016/j.biochi.2020.08.018. Epub 2020 Sep 3.
本文引用的文献
1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
3
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Microb Pathog. 2020 Aug;145:104228. doi: 10.1016/j.micpath.2020.104228. Epub 2020 Apr 25.
4
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
5
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
Clin Pharmacol Ther. 2020 Aug;108(2):201-211. doi: 10.1002/cpt.1857. Epub 2020 May 12.
6
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
7
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
8
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
9
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
10
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Zotero 插件